Wedbush Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $64
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $47 to $64.
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $47 to $64.